Abstract: A co-packaged product and containers for co-packaging two different substrates is disclosed. The co-packaged product comprises a first substrate wound into a roll having an interior space, and a second substrate is located within at least a portion of the interior space. In one embodiment, a paper towel roll has a wet wipe container located within the core of the paper towel.

Abstract: The present invention is related to hydrogel particles and aggregates formed therefrom having characteristics including, without limitation, shape-retentiveness, elasticity, controllable pore sizes and controllable degradation rates that render them useful for a wide variety of applications including, without limitation, the controlled release of biologically active substances, in vivo medical devices, tissue growth scaffolding and tissue replacement.

Abstract: Proposed is a novel soluble trauma-healing and hemostatic cellulose fiber capable of absorbing and readily dissolving hemorrhaging trauma loci when applied thereto and of promoting the hemostatic action of blood platelets and fibrin and cell adhesion to the trauma site. The coagulation protein-containing soluble trauma-healing and hemostatic cellulose fiber is produced in that after treatment of a natural or regenerated cellulose fiber with an aqueous sodium hydroxide solution, said fiber is carboxymethylated by reaction with a monochloro acetic acid solution for a given time (hours) in such a manner that the degree of partial substitution of the glucose units constituting the cellulose molecule (etherification degree) is 0.5-less than 1.0% and that, furthermore, the coagulation proteins fibrinogen, thrombin, and coagulation factor XIII are imparted by surface application or chemical bonding.

Abstract: In a process for the preparation of an article having a contact biocidal property, there is provided a polymer solution which contains atomic/metallic silver in suspension or complexed with the polymer and/or which contains a silver compound in solution, in suspension or complexed with the polymer. This polymer solution is applied to a substrate by impregnation or surface deposition, thus coating the substrate. Alternatively, it is possible to convert the polymer solution to a fibre, film, powder or foam, effectively forming the article from the polymer solution instead of coating an existing article. In either case, any silver compound present is reduced to atomic/metallic silver, and the resultant article is dried. Chitosan is preferably used as the polymer, although poly(vinyl alcohol) and sodium alginate can also be used. The polymer may be cross-linked at a suitable point in the process to insolubilize it.

Abstract: The invention relates to the use of a dopamine agonist in the form of an agent consisting of at least two spatially discrete compositions, of which one is a transdermal therapeutic system (TTS) containing the dopaminergic agent and another one or more are preparations for oral and/or parenteral application containing that same dopaminergic agent for the treatment of dopaminergically treatable diseases with the following elements: a) the TTS is continuously applied, b) within the duration of application in a) the composition for oral or parenteral dosage is administered.

Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.

Abstract: This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Abstract: A new and improved aqueous shaving cream composition and method of using the composition is disclosed. The aqueous composition comprises citric acid, hair keratin amino acids, stearic acids, boric acid, fumaric acid, SD Alcohol 40, cetyl alcohol, stearyl alcohol, calcium chloride, sodium chloride, camphor, hydroxyethylcellulose, calcium hydroxide, ammonium hydroxide, triethanolamine, gelatin, stearamidopropyl dimethylamine, methylchloroisothiazolone, methylisothiazolinone, cyclopentasiloxane, glycerin, dimeticonol, linseed oil, soybean oil, eucalyptus oil, propylene glycol, fragrance, methol, guar gum, DMDM hydantoin, sodium calcium alginate, panthenol, oleyl sarcosine, methylparaben, stearyl octyldimonium methosulfate, behenamidopropyl ethyldimonium ethosulfate, TEA-dodecylbenzenesulfonate, calcium sulfate, and disodium EDTA. The method of using the aqueous composition comprises the steps of getting, moistening, obtaining, placing, rubbing, shaving, and wiping.

Abstract: A composition for human consumption, comprising creatine and creatinine, the latter being in sufficient quantity to render creatine in an aqueous medium substantially stable, and a methyl xanthine; and a method of making the composition is provided.

Abstract: The invention relates to carrier particles for use in pharmaceutical compositions for the pulmonary administration of medicaments by means of dry powder inhalers. In particular, the invention relates to a novel technological process for obtaining a carrier modified so as to improve the efficiency of redispersion of active particles and hence increase the respirable fraction. After the treatment of the invention, the surface of said modified carrier particles can also be coated with a suitable additive so as to further improve the respirable fraction.

Abstract: Preparation of particles of an active substance having a layer of an additive at the particle surfaces, by dissolving both the active substance and the additive in a vehicle to form a target solution, and contacting the target solution with an anti-solvent fluid using a SEDS™ particle formation process, to cause the active substance and additive to coprecipitate. The additive is typically a protective additive, in particular a taste and/or odour masking agent. Also provided is a particulate coformulation made by the method, which has a finite gradient in the relative additive concentration, which concentration increases radially outwards from the active-rich core to the additive-rich surface of the particles.

Abstract: A water-dispersible vitamin composition containing Vitamins A, D3 or E, or a precursor thereof, an alkyl lactate and an emulsifier and is substantially free of water.

Abstract: The present invention concerns a food composition having a foodstuff and substantially pure eritadenine. The invention also concerns a food additive having a liquid or solid material intended to be added to a foodstuff, said material being supplemented with substantially pure eritadenine. Furthermore, the invention concerns methods for preparation of the food composition so as to provide a food composition having an increased level of eritadenine in comparison to the inherent eritadenine level of the foodstuff(s) included in the food composition.

Abstract: This invention relates to a convenient and safe product and method of applying glycopyrrolate topically in order to reduce excessive sweating in localized areas for those who suffer from this condition. This invention also relates to combining oral and topical delivery of glycopyrrolate to reduce excessive sweating and minimize side effects. This invention also relates to a convenient and safe product and method of applying glycopyrrolate topically to areas of compensatory sweating after endoscopic thoracic sympathectomy.

Abstract: A patch comprising an adhesive layer formed on one surface of a flexible support, wherein said adhesive layer containing a drug, an absorption enhancer and an adhesive comprising; (i) said drug is buprenorphine hydrochloride and/or buprenorphine, and (ii) said absorption enhancer is a mixture of polyoxyethylene sorbitan mono fatty acid ester having 6 to 20 of oxyethylene units and 12 to 18 of carbon number of fatty acid ester, and at least one selected from the group consisting of liquid higher fatty acid ester, 60 to 180 of molecular weight of liquid poly hydric alcohol, lactic acid and triacetin, and (iii) said adhesive is an acrylic-based adhesive.

Abstract: The present invention relates to a solid composition useful for tissue gluing, tissue sealing and hemostasis consisting essentially of a) a carrier which has at least one of the following physical properties: elasticity module in the range of 5-100 N/cm, density of 1-10 mg/cm3, chamber diameter of more than 0.75 mm and less than 4 mm and/or having a chamber diameter average below 3 mm and evenly distributed and fixed upon said carrier, b) solid fibrinogen, and c) solid thrombin. The carrier is a biodegradable polymer such as a polyhyaluronic acid, polyhydroxy acid, e.g. lactic acid, glucolic acid, hydroxybutanoic acid, a cellulose, gelatine or collagen, such as a collagen sponge, e.g. a collagen sponge consisting essentially of collagen type I fibers. The fibrinogen and thrombin are preferably human, purified from a natural source, or transgenic or recombinant human fibrinogen and/or thrombin.

Abstract: An implantable or insertable medical device is provided which comprises (a) a superoxide dismutase mimic and (b) a polymeric release region. Upon administration to a patient, the polymeric release region controls the release of the superoxide dismutase mimic, which is beneficially selected from a metal-chelate superoxide dismutase mimic and a nitroxide superoxide dismutase mimic. Also provided is a method of making an implantable or insertable medical device.

Abstract: The invention relates to a plaster containing an active agent, comprising at least one cover membrane and an active membrane which is based on a skin-compatible matrix containing a molecular sieve which is loaded with at least one active agent. The molecular sieve/active agent adduct releases the active agent when the active membrane comes into contact with the skin, in conjunction with the transpired water of the skin. The inventive plaster is characterised in that the molecular sieve/active agent adduct also contains water of crystallisation, to the extent that the molecular sieve is partially hydrated compared to a sufficient basic molar quantity (m) of water of crystallisation, the molecular sieve with the reduced molar quantity (m?) of water of crystallisation being loaded with the active agent (Z, Z1, Z2) so that when the active membrane comes into contact with the skin, water is absorbed and the active agent is desorbed, whereupon the water of crystallisation content of the molecular sieve increases.

Abstract: The present invention is a method of milling materials to form a fine powder with a median particle size below 10 micrometer which is suitable for inhalation and which has substantially no amorphous content generated during milling. The method is particularly suitable for milling materials which are soft. The method comprises milling the material in a fluid energy mill at reduced temperature using helium, or helium mixed with another gas, as milling fluid. Temperatures of ?30° C. or less are used.

Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.